Brief: Mirati Therapeutics posts Q1 basic EPS USD -3.18
09/05/2023 21:02
May 9 (Reuters) - Mirati Therapeutics Q1 product revenue USD 6.291 million. * Q1 net income USD -184.586 million * Q1 operating income USD -193.823 million * Q1 operating expenses USD 200.99 million * Q1 basic EPS USD -3.18
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)